• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Anzu Special Acquisition Corp I Announces Adjournment of Special Meeting of Stockholders

    2/9/23 4:15:00 PM ET
    $ANZU
    Blank Checks
    Finance
    Get the next $ANZU alert in real time by email

    Anzu Special Acquisition Corp I (the "Company") (NASDAQ: "ANZU," "ANZUU" and "ANZUWS"), announced today that it convened and then adjourned, without conducting any other business, the Company's special meeting of stockholders (the "Special Meeting") held on February 9, 2023. The Special Meeting has been adjourned until 9:30 a.m., Eastern time, on February 21, 2023 (the "Adjourned Special Meeting").

    The Adjourned Special Meeting will be held virtually via live webcast at https://web.lumiagm.com/274911563. The record date remains the close of business, Eastern Time, on January 17, 2023.

    At the Adjourned Special Meeting, stockholders will be asked to vote on a proposal to amend the Company's amended and restated certificate of incorporation to extend the date by which the Company must consummate an initial business combination from March 4, 2023 to September 30, 2023 or such earlier date as determined by the Company's board of directors (the "Extension Amendment Proposal"). The Extension Amendment Proposal is described in detail in the definitive proxy statement (the "Extension Proxy Statement") related to the Special Meeting filed by the Company with the Securities and Exchange Commission (the "SEC") on January 20, 2023.

    Stockholders may withdraw redemptions with the Company's consent at any time until the vote is taken with respect to the Extension Amendment Proposal. Stockholders may request to reverse their redemption by contacting the Company's transfer agent, American Stock Transfer & Trust Company, at 48 Wall Street, 22nd Floor, New York, New York 10005, Attn: Felix Orihuela (e-mail: [email protected]).

    Stockholders who have already voted and do not wish to change their vote do not need to vote again. If you have any questions or need any assistance voting, please contact the Company's proxy solicitor Morrow Sodali LLC by email at [email protected] or phone at (800) 662-5200.

    About Anzu Special Acquisition Corp I

    The Company is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company intends to focus on high-quality businesses with transformative technologies for industrial applications.

    Additional information on Anzu Special Acquisition Corp I is available at https://anzuspac.com/.

    Forward-Looking Statements

    This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-Looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Such statements may include, but are not limited to, statements regarding the anticipated timing of the Adjourned Special Meeting and the Company's initial business combination. The forward-looking statements contained in this press release reflect the Company's current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. The Company does not guarantee that the transactions and events described will happen as described (or that they will happen at all). These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, changes in domestic and foreign business, market, financial, political, and legal conditions; the failure of the Company to obtain the requisite approvals for the Extension Amendment Proposal; the amount of redemptions by the Company's public stockholders in connection with the Adjourned Special Meeting and an initial business combination; the inability of the parties to enter into a definitive agreement relating to an initial business combination on the timeline discussed or at all; the inability of the parties to successfully or timely consummate an initial business combination, including the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of an initial business combination or that the approval of stockholders is not obtained; failure to realize the anticipated benefits of an initial business combination; and other risks and uncertainties set forth in the section entitled "Risk Factors" in the Extension Proxy Statement, in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC on March 31, 2022 and in other reports the Company files with the SEC. If any of these risks materialize or the Company's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While forward-looking statements reflect the Company's good faith beliefs, they are not guarantees of future performance. The Company disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to the Company.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230209005746/en/

    Get the next $ANZU alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANZU

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ANZU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Anzu Special Acquisition Corp I Stockholders Approve Business Combination with Envoy Medical Corporation

    Anzu Special Acquisition Corp I (the "Company") (NASDAQ: "ANZU," "ANZUU" and "ANZUW"), announced today that its stockholders voted to approve the Business Combination Agreement with Envoy Medical Corporation ("Envoy"), and the transactions contemplated thereby (the "Business Combination") at the Company's special meeting of stockholders held on September 27, 2023 (the "Special Meeting"). Pursuant to the Business Combination Agreement, Merger Sub will merge with and into Envoy, with Envoy surviving the merger as a wholly owned subsidiary of the Company (the "Merger"). Following the closing of the Merger (the "Closing"), the Company will be renamed "Envoy Medical, Inc.", which is referred t

    9/27/23 4:10:00 PM ET
    $ANZU
    Blank Checks
    Finance

    Anzu Special Acquisition Corp I Announces Adjournment of Special Meeting of Stockholders

    Anzu Special Acquisition Corp I (the "Company") (NASDAQ: "ANZU," "ANZUU" and "ANZUWS"), announced today that it convened and then adjourned, without conducting any other business, the Company's special meeting of stockholders (the "Special Meeting") held on February 9, 2023. The Special Meeting has been adjourned until 9:30 a.m., Eastern time, on February 21, 2023 (the "Adjourned Special Meeting"). The Adjourned Special Meeting will be held virtually via live webcast at https://web.lumiagm.com/274911563. The record date remains the close of business, Eastern Time, on January 17, 2023. At the Adjourned Special Meeting, stockholders will be asked to vote on a proposal to amend the Company's

    2/9/23 4:15:00 PM ET
    $ANZU
    Blank Checks
    Finance

    $ANZU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lucas Brent T. bought $11,990 worth of shares (12,380 units at $0.97), increasing direct ownership by 11% to 120,831 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    11/24/23 4:09:42 PM ET
    $ANZU
    Blank Checks
    Finance

    $ANZU
    SEC Filings

    View All

    SEC Form S-1/A filed by Anzu Special Acquisition Corp I (Amendment)

    S-1/A - Envoy Medical, Inc. (0001840877) (Filer)

    2/14/24 9:17:12 PM ET
    $ANZU
    Blank Checks
    Finance

    SEC Form S-1 filed by Anzu Special Acquisition Corp I

    S-1 - Envoy Medical, Inc. (0001840877) (Filer)

    1/18/24 5:09:23 PM ET
    $ANZU
    Blank Checks
    Finance

    SEC Form 10-Q/A filed by Anzu Special Acquisition Corp I (Amendment)

    10-Q/A - Envoy Medical, Inc. (0001840877) (Filer)

    1/17/24 4:16:52 PM ET
    $ANZU
    Blank Checks
    Finance

    $ANZU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Taylor Glen A (Amendment)

    4/A - Envoy Medical, Inc. (0001840877) (Issuer)

    12/4/23 4:57:21 PM ET
    $ANZU
    Blank Checks
    Finance

    Lucas Brent T. bought $11,990 worth of shares (12,380 units at $0.97), increasing direct ownership by 11% to 120,831 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    11/24/23 4:09:42 PM ET
    $ANZU
    Blank Checks
    Finance

    SEC Form 4 filed by Taylor Glen A

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    11/22/23 4:11:45 PM ET
    $ANZU
    Blank Checks
    Finance

    $ANZU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Anzu Special Acquisition Corp I (Amendment)

    SC 13G/A - Envoy Medical, Inc. (0001840877) (Subject)

    2/12/24 4:30:47 PM ET
    $ANZU
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Anzu Special Acquisition Corp I (Amendment)

    SC 13G/A - Anzu Special Acquisition Corp I (0001840877) (Subject)

    2/13/23 12:29:11 PM ET
    $ANZU
    Blank Checks
    Finance

    SEC Form SC 13G filed by Anzu Special Acquisition Corp I

    SC 13G - Anzu Special Acquisition Corp I (0001840877) (Subject)

    2/14/22 2:25:31 PM ET
    $ANZU
    Blank Checks
    Finance